HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Foramen magnum stenosis and midface hypoplasia in C-type natriuretic peptide-deficient rats and restoration by the administration of human C-type natriuretic peptide with 53 amino acids.

Abstract
C-type natriuretic peptide (CNP)-knockout (KO) rats exhibit impaired skeletal growth, with long bones shorter than those in wild-type (WT) rats. This study compared craniofacial morphology in the CNP-KO rat with that in the Spontaneous Dwarf Rat (SDR), a growth hormone (GH)-deficient model. The effects of subcutaneous administration of human CNP with 53 amino acids (CNP-53) from 5 weeks of age for 4 weeks on craniofacial morphology in CNP-KO rats were also investigated. Skulls of CNP-KO rats at 9 weeks of age were longitudinally shorter and the foramen magnum was smaller than WT rats. There were no differences in foramen magnum stenosis and midface hypoplasia between CNP-KO rats at 9 and 33 weeks of age. These morphological features were the same as those observed in CNP-KO mice and activated fibroblast growth factor receptor 3 achondroplasia-phenotype mice. In contrast, SDR did not exhibit foramen magnum stenosis and midface hypoplasia, despite shorter stature than in control rats. After administration of exogenous CNP-53, the longitudinal skull length and foramen magnum size in CNP-KO rats were significantly greater, and full or partial rescue was confirmed. The synchondrosis at the cranial base in CNP-KO rats is closed at 9 weeks, but not at 4 weeks of age. In contrast, synchondrosis closure in CNP-KO rats treated with CNP-53 was incomplete at 9 weeks of age. Administration of exogenous CNP-53 accelerated craniofacial skeletogenesis, leading to improvement in craniofacial morphology. As these findings in CNP-KO rats are similar to those in patients with achondroplasia, treatment with CNP-53 or a CNP analog may be able to restore craniofacial morphology and foramen magnum size as well as short stature.
AuthorsTakafumi Yotsumoto, Naomi Morozumi, Mayumi Furuya, Toshihito Fujii, Keisho Hirota, Yohei Ueda, Kazumasa Nakao, Shigeki Yamanaka, Kazunori Yoshikiyo, Sayaka Yoshida, Tomonari Nishimura, Yasuyuki Abe, Toshimasa Jindo, Hiroyuki Ogasawara, Akihiro Yasoda
JournalPloS one (PLoS One) Vol. 14 Issue 5 Pg. e0216340 ( 2019) ISSN: 1932-6203 [Electronic] United States
PMID31120905 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Natriuretic Peptide, C-Type
Topics
  • Achondroplasia (drug therapy)
  • Animals
  • Bone Development
  • Constriction, Pathologic
  • Face (abnormalities)
  • Foramen Magnum (pathology)
  • Humans
  • Natriuretic Peptide, C-Type (deficiency, therapeutic use)
  • Rats
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: